Wenn Sie das Fenster schließen, wird Ihre Konfiguration nicht gespeichert, es sei denn, Sie haben Ihren Artikel in die Bestellung aufgenommen oder zu Ihren Favoriten hinzugefügt.
Klicken Sie auf OK, um das MILLIPLEX® MAP-Tool zu schließen oder auf Abbrechen, um zu Ihrer Auswahl zurückzukehren.
Wählen Sie konfigurierbare Panels & Premixed-Kits - ODER - Kits für die zelluläre Signaltransduktion & MAPmates™
Konfigurieren Sie Ihre MILLIPLEX® MAP-Kits und lassen sich den Preis anzeigen.
Konfigurierbare Panels & Premixed-Kits
Unser breites Angebot enthält Multiplex-Panels, für die Sie die Analyten auswählen können, die am besten für Ihre Anwendung geeignet sind. Unter einem separaten Register können Sie das Premixed-Cytokin-Format oder ein Singleplex-Kit wählen.
Kits für die zelluläre Signaltransduktion & MAPmates™
Wählen Sie gebrauchsfertige Kits zur Erforschung gesamter Signalwege oder Prozesse. Oder konfigurieren Sie Ihre eigenen Kits mit Singleplex MAPmates™.
Die folgenden MAPmates™ sollten nicht zusammen analysiert werden: -MAPmates™, die einen unterschiedlichen Assaypuffer erfordern. -Phosphospezifische und MAPmate™ Gesamtkombinationen wie Gesamt-GSK3β und Gesamt-GSK3β (Ser 9). -PanTyr und locusspezifische MAPmates™, z.B. Phospho-EGF-Rezeptor und Phospho-STAT1 (Tyr701). -Mehr als 1 Phospho-MAPmate™ für ein einziges Target (Akt, STAT3). -GAPDH und β-Tubulin können nicht mit Kits oder MAPmates™, die panTyr enthalten, analysiert werden.
.
Bestellnummer
Bestellinformationen
St./Pkg.
Liste
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Wählen Sie bitte Spezies, Panelart, Kit oder Probenart
Um Ihr MILLIPLEX® MAP-Kit zu konfigurieren, wählen Sie zunächst eine Spezies, eine Panelart und/oder ein Kit.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Spezies
Panelart
Gewähltes Kit
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
96-Well Plate
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
Weitere Reagenzien hinzufügen (MAPmates erfordern die Verwendung eines Puffer- und Detektionskits)
Menge
Bestellnummer
Bestellinformationen
St./Pkg.
Listenpreis
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Platzsparende Option Kunden, die mehrere Kits kaufen, können ihre Multiplex-Assaykomponenten in Kunststoffbeuteln anstelle von Packungen erhalten, um eine kompaktere Lagerung zu ermöglichen.
Dieser Artikel wurde zu Ihren Favoriten hinzugefügt.
Das Produkt wurde in Ihre Bestellung aufgenommen
Sie können nun ein weiteres Kit konfigurieren, ein Premixed-Kit wählen, zur Kasse gehen oder das Bestell-Tool schließen.
03-251
Sigma-AldrichRIPAb+™ IGF2BP2 Antibody
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages.
More>>IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages. Less<<
RIPAb+™ IGF2BP2 Antibody: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.
RIPAb+ antibodies are evaluated using the RNA Binding Protein Immunoprecipitation (RIP) assay. Each RIPAb+ antibody set includes a negative control antibody to ensure specificity of the RIP reaction and is verified for the co-immunoprecipitation of RNA associated specifically with the immunoprecipitated RNA-binding protein of interest. Where appropriate, the RIPAb+ set also includes quantitative RT-PCR control primers (RIP Primers) to biologically validate your IP results by successfully co-precipitating the specific RNA targets, such as messenger RNAs. The qPCR protocol and primer sequences are provided, allowing researchers to validate RIP protocols when using the antibody in their experimental context. If a target specific assay is not provided, the RIPAb+ kit is validated using an automated microfluidics-based assay by enrichment of detectable RNA over control immunoprecipitation. IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages. IGF2BP1, 2, and 3 bind the UTR region of IGF2 transcripts, and are implicated in the transport of RNA targets, to enable protein synthesis at specific locations in the cytoplasm. Research has shown that the IGF2 gene may be involved in ovarian cancer.
Alternate Names
Insulin-like growth factor 2 mRNA-binding protein 2
IGF2 mRNA-binding protein 2
IMP-2
Hepatocellular carcinoma autoantigen p62
IGF-II mRNA-binding protein 2
VICKZ family member 2
Background Information
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is a member of the IGF-II mRNA binding protein family that posttranscriptionally regulates IGF2 during developmental stages. IGF2 mRNA-binding protein family members (IGF2BP1, 2 and 3) bind UTR region of IGF2 transcripts and are implicated in the transport of RNA targets to enable protein synthesis at specific locations in the cytoplasm. Studies have indicated variations in the IGF2BP2 gene may affect fetal glucose metabolism and plays a role in type 2 diabetes. In addition to playing a role in glucose metabolism and dieabetes, the insulin-like growth factor (IGF) signaling axis plays an important role in cancer biology. Research has shown IGF2 to be emerging as an important gene for ovarian cancer.
References
Product Information
Format
Purified
Control
Includes normal mouse IgG and primers specific for human IGF2 mRNA.
Presentation
Anti-IGF2BP2 (Mouse Monoclonal). One vial containing 12.5 µg protein G purified monoclonal in buffer containing 0.1 M Tris-glycine (pH 7.4), 150mM NaCl, 0.05% sodium azide before the addition of glycerol to 30%. Store at -20° C. Concentration: 0.176 mg/mL Normal mouse IgG. One vial containing 125 µg purified mouse IgG in 125 µL storage buffer containing 0.1% sodium azide. Store at -20°C. RIP Primer IGF2. One vial containing 75 μL of 5 μM of each primer specific for human IGF2 mRNA. Store at -20°C. FOR: GCG GCT TCT ACT TCA GCA G REV: CAG GTG TCA TAT TGG AAG AAC
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) is a member of the IGF-II mRNA-binding protein family that post-transcriptionally regulates IGF2 during developmental stages.
Key Applications
Western Blotting
RNA Binding Protein Immunoprecipitation (RIP)
Application Notes
Western Blot Analysis: Representative lot data. HepG2 cell lysate was probed with Anti-IGF2BP2, clone 5E10-3E1 (1:20,000 dilution). Proteins were visualized using a Goat Anti-Mouse IgG secondary antibody conjugated to HRP and a chemiluminescence detection system. Arrow indicates IGF2BP2 (~66 kDa). Note: An uncharacterized band appears at ~50 kDa in some lysates.
Biological Information
Immunogen
Histidine-tagged recombinant protein corresponding to human IGF2BP2
Clone
5E10-3E1
Concentration
Please refer to the Certificate of Analysis for the lot-specific concentration.
This gene encodes a member of the IGF-II mRNA-binding protein (IMP) family. The protein encoded by this gene contains several four KH domains and two RRM domains. It functions by binding to the 5' UTR of the insulin-like growth factor 2 (IGF2) mRNA and regulating IGF2 translation. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008].
FUNCTION: Binds to the 5'-UTR of the insulin-like growth factor 2 (IGF2) mRNAs. Binding is isoform-specific. May regulate translation of target mRNAs.
SUBUNIT STRUCTURE: Interacts with HNRPD and IGF2BP1.
SUBCELLULAR LOCATION: Cytoplasm. Note: Localized in cytoplasmic mRNP granules containing untranslated mRNAs. Localizes at the connecting piece and the tail of the spermatozoa.
TISSUE SPECIFICITY: Expressed in oocytes, granulosa cells of small and growing follicles, Leydig cells, spermatogonia and semen (at protein level). Expressed in testicular cancer (at protein level). Expressed weakly in heart, placenta, skeletal muscle, bone marrow, colon, kidney, salivary glands, testis and pancreas. Detected in fetal liver, fetal ovary, gonocytes and interstitial cells of the testis.
DOMAIN: The third and fourth KH domains are important for binding to the untranslated region (UTR) of target mRNA.
MISCELLANEOUS: Autoantibodies against IGF2BP2 are detected in sera from some patients with hepatocellular carcinoma.
SEQUENCE SIMILARITIES: Belongs to the RRM IMP/VICKZ family.
Contains 4 KH domains.
Contains 2 RRM (RNA recognition motif) domains.
SEQUENCE CAUTION: The sequence AAH21290.1 differs from that shown. Reason: Erroneous initiation.
Molecular Weight
~66 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality Assurance
RNA Binding Protein Immunoprecipitation: Representative lot data RIP Lysate prepared from 293 cells (2 X 10E7 cell equivalents per IP) were subjected to immunoprecipitation using 1.25 µg of either a normal mouse IgG or 1.25 µg Anti-IGF2BP2 antibody and the Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Cat. # 17-700). Successful immunoprecipitation of IGF2BP2-associated RNA was verified by qPCR using RIP Primers IGF2, (Figure 1). Please refer to the Magna RIP™ (Cat. # 17-700) or EZ-Magna RIP™ (Cat. # 17-701) protocol for experimental details.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
Packaging Information
Material Size
10 assays
Material Package
10 assays per set. Recommended use: 1.25 μg of antibody per RIP (dependent upon biological context).
The recognition of stress-induced ligands by the activating receptor NKG2D expressed on cytotoxic lymphocytes is crucial for the prevention and containment of various diseases and is also one of the best-studied examples of how danger is sensed by the immune system. Still, however, the mechanisms leading to the expression of the NKG2D ligands are far from being completely understood. Here, we use an unbiased and systematic RNA pull-down approach combined with mass spectrometry to identify six RNA-binding proteins (RBPs) that bind and regulate the expression of MICB, one of the major stress-induced ligands of NKG2D. We further demonstrate that at least two of the identified RBPs function during genotoxic stress. Our data provide insights into stress recognition and hopefully open new therapeutic venues.
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway. Li, Z; Zhang, Y; Ramanujan, K; Ma, Y; Kirsch, DG; Glass, DJ Cancer Res
73
3041-50
2013
Embryonic rhabdomyosarcoma (ERMS) is the most common soft-tissue tumor in children. Here, we report the identification of the minor groove DNA-binding factor high mobility group AT-hook 2 (HMGA2) as a driver of ERMS development. HMGA2 was highly expressed in normal myoblasts and ERMS cells, where its expression was essential to maintain cell proliferation, survival in vitro, and tumor outgrowth in vivo. Mechanistic investigations revealed that upregulation of the insulin-like growth factor (IGF) mRNA-binding protein IGF2BP2 was critical for HMGA2 action. In particular, IGF2BP2 was essential for mRNA and protein stability of NRAS, a frequently mutated gene in ERMS. shRNA-mediated attenuation of NRAS or pharmacologic inhibition of the MAP-ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) effector pathway showed that NRAS and NRAS-mediated signaling was required for tumor maintenance. Taken together, these findings implicate the HMGA2-IGFBP2-NRAS signaling pathway as a critical oncogenic driver in ERMS.
